Navigation Links
Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)
Date:3/24/2009

ection, resulting in one third of the 33 million HIV sufferers worldwide infected with TB. Left untreated, 90 percent of these people will die within months of first contracting the disease, reinforcing the urgent need for an accurate and rapid test.

"The need for accurate and rapid detection of tuberculosis is becoming increasingly acute with the development of drug resistant strains and the growing at-risk populations in the developing world," said John Bishop, Cepheid's Chief Executive Officer. "The GeneXpert System has a unique level of technical capability never before seen in molecular diagnostics and this capability is on full display with the Xpert MTB/RIF test. Clinicians will now be able to obtain dependable test results for not only detection of TB but simultaneous determination of whether or not it is a drug resistant strain in virtually any clinical setting. Appropriate therapeutic management has been a significant factor in the development of drug resistant strains of tuberculosis and the availability of the Xpert MTB/RIF test should be a breakthrough technological leap forward in helping to ensure proper therapeutic management and in helping to halt transmission. We are expecting to make this test available as a CE IVD Mark product next month."

Xpert MTB/RIF not only detects the presence of TB, but also identifies whether it is resistant to Rifampicin, a common first-line drug for treatment of the disease and a reliable surrogate marker of strains that are multidrug-resistant (MDR-TB). The test is expected to enable physicians to dramatically improve patient outcomes -- possible only with on-demand, actionable results to guide therapy decisions within the timeframe of an initial patient visit.

"Multidrug-resistant TB is becoming increasingly prevalent throughout the world, making TB harder to treat with the usual treatment regimen that includes Rifampicin," said David H. Persing, M.D., Ph.D., Cephei
'/>"/>

SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
2. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
3. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
4. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
5. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
6. Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
7. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
8. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
9. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
10. Cepheid Reports Fourth Quarter and Full Year 2007 Results
11. Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 AACC welcomed ... the 2015 AACC Annual Meeting & Clinical Lab ... July 26–30. The meeting showcased revolutionary advancements in ... ability of healthcare providers to diagnose patients quickly ... medical treatment. As of Wednesday, ...
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report on the ... state of the global Propanol market with a focus on the Chinese situation. Major ... Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... , July 30, 2015 Ascendis ... company that applies its innovative TransCon technology to ... top-line results from a six-month Phase 2 study ... TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal children ... "We are extremely pleased with the top-line results ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... CHICAGO, July 22 Research presented at the American ... monitoring cardiac transplant patients with the Urine NGAL assay on ... toxicity and adjust doses of cyclosporine drugs to prevent possible ... In a scientific poster presented at AACC today ...
... , , PHILADELPHIA, July 22 ... centralized ECG and eClinical technology, ePRO, and other services to the ... new Vice President of Project Management, Tammy Miller. Ms. Miller will ... In this new role, Ms. Miller will be responsible for the ...
... , , CHICAGO, July 22 Research ... that an assay developed by Abbott for simultaneous detection of both HIV ... in this study compared to HIV antibody-only assays. Earlier detection was ... , "The ability to use a blood test to ...
Cached Biology Technology:Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients 2ERT Appoints New Vice President of Project Management 2ERT Appoints New Vice President of Project Management 3Abbott HIV Test Demonstrates Earlier Disease Detection 2Abbott HIV Test Demonstrates Earlier Disease Detection 3
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
(Date:7/31/2015)... 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT ... method to advance crypto-currencies such as Bitcoin into the ... uniform way to manage all payments.  ...
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... to protect chickens, cats and humans against deadly flu pandemics, ... the Journal of General Virology . The vaccine protects ... be given to birds while they are still in their ... emergence of bird flu has posed a major challenge to ...
... St. Louis operates one of the largest and fastest ... in the western hemisphere. With the addition of a ... aroid species from Ecuador, the Garden,s permanent collection of ... of six million specimens. A herbarium is essentially ...
... counter-terrorism symposium tomorrow at NJIT from 8:30 a.m. - ... ways to secure schools, health and transportation facilities, protect ... and more. Presenters will include NJ State ... Homeland Security and Preparedness, U.S. Coast Guard and NJ ...
Cached Biology News:Bird flu vaccine protects people and pets 2Missouri Botanical Garden mounts milestone 6 millionth herbarium specimen 2Missouri Botanical Garden mounts milestone 6 millionth herbarium specimen 3
... These precision 5mm diameter, 7 inch long ... glass for compatibility with ground joints, valves, and ... NMR spectrometers running from 300 to 500MHz. They ... an I.D. of 4.20 + 0.013-0.000mm. These NMR ...
... for nucleic acid electrophoresis in agarose ... Preparation Quantity Equivalency: A final concentration ... stock solution can be made in ... Dye content ~ 75% Special ...
Preparation TW--Compatibility: Push-on end cap seals suitable up to 70 C only -Hybridization Tube for Model HB-1D -Comp Dim: 200 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-12...
... GenElute Gel Extraction Kit combines silica- binding technology ... column format. DNA fragments of interest are extracted ... the gel. The Gel Solubilization Solution can dissolve ... either TBE or TAE buffer. Extracted DNA fragments ...
Biology Products: